Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
10592studies shown
Showing 2,773-2,784 of 10,592
Drug study icon
CompletedNCT01655680

ABT-126 for schizophrenia

This study is completed in the United States, in the United Kingdom, and in Russia. It is testing ABT-126 for schizophrenia.

In United States
SchizophreniaDrugFrom 20 Years to 65 Years
Countries
United States, United Kingdom, Russia
Sponsor
AbbVie (prior sponsor, Abbott)
Condition
Schizophrenia
Drug study icon
CompletedNCT01192880

Bitopertin for schizophrenia

This study is completed in the United States, in Bulgaria, in China, .... It is testing bitopertin for schizophrenia.

In United States
SchizophreniaDrugOver 18 Years
Countries
United States, Bulgaria, China, ...
Sponsor
Hoffmann-La Roche
Condition
Schizophrenia
Drug study icon
CompletedNCT02942004

SAGE-547 for depression

This study is completed in the United States. It is testing SAGE-547 for depression.

In United States
DepressionDrugFrom 18 Years to 45 Years
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc.
Condition
Depression
Drug study icon
WithdrawnNCT05344365

Iloperidone for Schizophrenia

This study was withdrawn in the United States. It is testing iloperidone for Schizophrenia.

In United States
SchizophreniaDrugOver 65 Years
Countries
United States
Sponsor
Vanda Pharmaceuticals
Condition
Schizophrenia
Drug study icon
CompletedNCT04712734

Iloperidone Long-acting Injection (LAI) for schizophrenia

This study is completed in the United States. It is testing Iloperidone Long-acting Injection (LAI) for schizophrenia.

In United States
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Vanda Pharmaceuticals
Condition
Schizophrenia
Drug study icon
Active Not RecruitingNCT06817356

Mazdutide Compared With Placebo in people with Addiction

This study is active but not recruiting in the United States. It is testing mazdutide Compared With Placebo for Addiction.

In United States
AddictionDrugFrom 21 Years to 65 Years
Countries
United States
Sponsor
Eli Lilly and Company
Condition
Addiction
Behavioral study icon
Enrolling By InvitationNCT05814653

Primary Care Treatment for Eating disorders

This study is enrolling by invitation in the United States. It is testing primary Care Treatment for Eating disorders.

In United States
Eating disordersBehavioralFrom 7 Years to 18 Years
Countries
United States
Sponsor
Mayo Clinic
Condition
Eating disorders
Behavioral study icon
CompletedNCT05686239

RL-007 for schizophrenia

This study is completed in the United States, in Bulgaria, in Czechia, .... It is testing RL-007 for schizophrenia.

In United States
SchizophreniaBehavioralFrom 18 Years to 55 Years
Countries
United States, Bulgaria, Czechia, ...
Sponsor
Recognify Life Sciences
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.